Skip to main content

Mintz Life Sciences Deal Activity (April – June 2020)

M&A

  • Represented Censa Pharmaceuticals, Inc. in its sale to PTC Therapeutics, Inc. (May 2020)
  • Represented Neurotrope, Inc. in its merger agreement with Metuchen Pharmaceuticals, LLC to form Petros Pharmaceuticals, a men’s health company (May 2020)
  • Represented HealthpointCapital, a private equity firm focused on the musculoskeletal industry, in its acquisition of a majority stake in IlluminOss Medical Inc. (May 2020)
  • Served as U.S. legal counsel to QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a provider of life science and molecular diagnostic solutions, in its $11.5B sale transaction with Thermo Fisher Scientific Inc. (NYSE: TMO), a manufacturer of scientific instrumentation, equipment, software, and services (announced March 2020)

VC

  • Represented Matrix Capital Management in its $43.7M Series C investment in a clinical data analytics company (June 2020)
  • Represented Matrix Capital Management in its $25M Series D Investment in a cancer therapeutic company (June 2020)
  • Represented Inhibrx, Inc. in its $15M Convertible Note financing (April 2020)
  • Represented MitoLab Inc. in its $3M Series Seed financing (April 2020)

Capital Markets 

Represented the issuer:

  • Evofem Inc. in its $100M public offering underwritten by Morgan Stanley, Piper Sandler, Oppenheimer & Co. Inc., H.C. Wainwright & Co., LLC (June 2020)
  • Viela Bio, Inc. in its $169M public offering underwritten by Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Guggenheim Securities (June 2020)
  • Bellerophon Therapeutics, Inc. in its $25M public offering underwritten by Jefferies and concurrent $15M registered direct offering (May 2020)
  • Caladrius Biosciences, Inc. in its $4.3M registered direct offering placed by H.C. Wainwright & Co. and Arcadia Securities (May 2020)
  • Evofem Inc. in its $25M PIPE financing (April 2020)

Represented the underwriters:

  • Acceleron Pharma Inc. in its $450M public offering underwritten by J.P. Morgan, SVB Leerink, Cowen, Barclays, Credit Suisse, Piper Sandler and H.C. Wainwright & Co. (June 2020)
  • Soleno Therapeutics, Inc. in its $50M public offering underwritten by Guggenheim Securities, Oppenheimer & Co. and Laidlaw & Company (UK) Ltd. (June 2020)
  • Soliton, Inc. in its $35M public offering underwritten by Cantor, Oppenheimer & Co. and Maxim Group LLC (June 2020)
  • Celsion Corporation in its $10M registered direct offering underwritten by Oppenheimer & Co. Inc. (June 2020)
  • Leap Therapeutics, Inc. in its $45M public offering underwritten by Piper Sandler, Raymond James, Baird, H.C. Wainwright & Co. and Ladenburg Thalmann (June 2020)
  • Cerecor Inc. in its $33M public offering underwritten by Oppenheimer & Co. Inc. (June 2020)
  • Mersana Therapeutics, Inc. in its $152M public offering underwritten by Cowen, SVB Leerink, Wedbush PacGrow, Baird and H.C. Wainwright & Co. (May 2020)
  • Geron Corporation in its $150M public offering underwritten by Stifel, MTS Health Partners, Needham & Company, BTIG and H.C. Wainwright & Co. (May 2020)
  • NeuBase Therapeutics, Inc. in its $31.5M public offering underwritten by Oppenheimer & Co., BTIG, Chardan and National Securities Corporation (April 2020)
  • Fennec Pharmaceuticals Inc. in its $30M public offering underwritten by Cantor and Wedbush PacGrow (April 2020)
  • Bionano Genomics, Inc. in its $18M public offering underwritten by Oppenheimer & Co. Inc., Roth Capital Partners and Maxim Group, LLC (April 2020)

Represented the sales agent / placement agent:

  • Compass Therapeutics in its $60M private placement with Raymond James, B. Riley FBR, and Katalyst Securities, LLC as placement agents (June 2020)
  • Ocuphire Pharma, Inc. in its $21.5M private placement with Cantor and Canaccord Genuity as placement agents (June 2020)
  • Axovant Gene Therapies Ltd. In its $25M at-the-market offering with SVB Leerink as sales agent (April 2020)

Subscribe To Viewpoints